Tyrosine Kinase Inhibitors in pediatric chronic myeloid leukemia: a focused review of clinical trials

Tyrosine Kinase Inhibitors in pediatric chronic myeloid leukemia: a focused review of clinical trials

Tyrosine Kinase Inhibitors (TKIs) is revolutionizing the management of pediatric Chronic Myeloid Leukemia (CML), offering alternatives to Allogeneic Hematopoietic Stem Cell Transplantation (AHSCT). We conducted a comprehensive review of 16 Randomized Controlled Trials (RCTs) encompassing 887 pediatr...

Full description

Bibliographic Details
Main Authors:	Fateen Ata, Maria Benkhadra, Rola Ghasoub, Liam J. Fernyhough, Nabil E. Omar, Abdulqadir J. Nashwan, Mahmood B. Aldapt, Kamran Mushtaq, Nancy A. Kassem, Mohamed A. Yassin
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2023-12-01
Series:	Frontiers in Oncology
Subjects:	Tyrosine Kinase Inhibitors TKI pediatric chronic myeloid leukemia CML Imatinib
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2023.1285346/full

Similar Items

WHO 2016 Definition of Chronic Myeloid Leukemia and Tyrosine Kinase Inhibitors
by: İbrahim C. Haznedaroğlu, et al.
Published: (2020-02-01)

Bullous Pemphigoid Occurring after Stopping Imatinib Therapy of CML: Is a Continuation of Post-Treatment Follow-Up Needed?
by: Alexander Yakobson, et al.
Published: (2023-09-01)

Comparative Assessment of Echocardiographic Patterns Among Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitor and Healthy Controls
by: Bamgboje AO, et al.
Published: (2022-02-01)

Monitoring the response to tyrosine kinase inhibitor (TKI) treatment in chronic myeloid leukemia (CML)
by: Ibrahim C. Haznedaroglu
Published: (2014-08-01)

REPEATED THERAPEUTIC LEUKAPHERESIS - A SOLE TREATMENT DURING PREGNANCY AS A BRIDGE BEFORE TYROSINE KINASE INHIBITORS FOR A PREGNANT WOMAN WITH CHRONIC MYELOGENOUS LEUKEMIA – A CASE REPORT AND DISCUSSION
by: Ivan Tonev, et al.
Published: (2025-01-01)

Survival of Patients with CML on Imatinib Experience with 44 Iraqi Patients
by: Ali M. Jawad, et al.
Published: (2008-10-01)

Therapeutic options for chronic myeloid leukemia following the failure of second-generation tyrosine kinase inhibitor therapy
by: Binsah George, et al.
Published: (2024-07-01)

Imatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia
by: Gholamreza Bahoush, et al.
Published: (2009-09-01)

Imatinib Mesylate (Glivec) in Pediatric Chronic Myelogenous Leukemia
by: Gholamreza Bahoush, et al.
Published: (2009-07-01)

The pro-metastasis tyrosine phosphatase, PRL-3 (<it>PTP4A3</it>), is a novel mediator of oncogenic function of BCR-ABL in human chronic myeloid leukemia
by: Zhou Jianbiao, et al.
Published: (2012-09-01)

Allogeneic Haematopoietic Stem Cell Transplantation for Chronic Myeloid Leukaemia in the Era of Tyrosine Kinase Inhibitors
by: Ahmet Emre Eskazan, et al.
Published: (2018-08-01)

The Cardiovascular Event Risk Associated with Tyrosine Kinase Inhibitors and the Lipid Profile in Patients with Chronic Myeloid Leukemia
by: María Nieves Saez Perdomo, et al.
Published: (2024-03-01)

The Direct and Indirect Effects of Tyrosine Kinase Inhibitors on the Cardiovascular System in Chronic Myeloid Leukemia
by: Alessandro Costa, et al.
Published: (2023-07-01)

Debating Frontline Therapy in Chronic Myeloid Leukemia
by: Xia Bi, et al.
Published: (2021-09-01)

Are Successful Pregnancies an Achievable Goal in Patients with Chronic Myeloid Leukaemia?
by: Zhanet Grudeva-Popova, et al.
Published: (2019-08-01)

Imatinib therapy of chronic myeloid leukemia significantly reduces carnitine cell intake, resulting in adverse events
by: Pavel Burda, et al.
Published: (2024-10-01)

Chronic myeloid leukaemia in the South African public health setting: Are we reaching the European LeukemiaNet targets for frontline therapy?
by: Tshifhiwa B. Sikhipha, et al.
Published: (2020-12-01)

Cryptotanshinone enhances the efficacy of Bcr-Abl tyrosine kinase inhibitors via inhibiting STAT3 and eIF4E signalling pathways in chronic myeloid leukaemia
by: Rubin Cheng, et al.
Published: (2021-01-01)

Vaccination With Live Attenuated Vaccines in Four Children With Chronic Myeloid Leukemia While on Imatinib Treatment
by: Claudia Bettoni da Cunha-Riehm, et al.
Published: (2020-04-01)

Atypical presentation of chronic myeloid leukemia with visual disturbance
by: Rachana Chennamaneni, et al.
Published: (2018-01-01)

Second-Line Therapy Tyrosine Kinase Inhibitor for Chronic Phase Chronic Myeloid Leukemia Resistant to Imatinib
by: Chici Pratiwi, et al.
Published: (2022-12-01)

Evaluation of Imatinib adherence in chronic myeloid leukemia patients in Babylon Province, Iraq
by: Athmar Kadhim Gatea, et al.
Published: (2023-01-01)

Tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia: a single-institution experience
by: Kamal Chamoun, et al.
Published: (2019-01-01)

Dilemmas in the Diagnosis and Management of CML in Pakistan
by: Sahrish Khan, et al.
Published: (2024-12-01)

Achieving optimal response at 12 months is associated with a better health-related quality of life in patients with chronic myeloid leukemia: a prospective, longitudinal, single center study
by: Lu Yu, et al.
Published: (2018-08-01)

An observational study on risk of secondary cancers in chronic myeloid leukemia patients in the TKI era in the United States
by: Vivek Kumar, et al.
Published: (2018-02-01)

Baseline blood count levels increase odds of cytopenia among CML patients in Kenya: a case control study
by: Angela McLigeyo, et al.
Published: (2022-02-01)

Targeting integrated stress response with ISRIB combined with imatinib treatment attenuates RAS/RAF/MAPK and STAT5 signaling and eradicates chronic myeloid leukemia cells
by: Wioleta Dudka, et al.
Published: (2022-12-01)

The Importance of Mutational Analysis in Chronic Myeloid Leukaemia for Treatment Choice
by: Hugues de Lavallade, et al.
Published: (2016-11-01)

Modulation of Plasma 25-Hydroxyvitamin D3 Level by Imatinib Mesylate in Patients with Chronic Myelogenous Leukemia: The Role of Uptake and Efflux Transporters
by: Mervat M. Omran, MD, et al.
Published: (2022-01-01)

Multidisciplinary management in chronic myeloid leukemia improves cardiovascular risk measured by SCORE
by: Alberto Blanco Sánchez, et al.
Published: (2023-07-01)

Tyrosine Kinase Inhibitors Play an Antiviral Action in Patients Affected by Chronic Myeloid Leukemia: A Possible Model Supporting Their Use in the Fight Against SARS-CoV-2
by: Sara Galimberti, et al.
Published: (2020-09-01)

Modulating retinoid-X-receptor alpha (RXRA) expression sensitizes chronic myeloid leukemia cells to imatinib in vitro and reduces disease burden in vivo
by: Bharathi M. Rajamani, et al.
Published: (2023-05-01)

Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia
by: Mario Tiribelli, et al.
Published: (2019-08-01)

Inhibition of Xanthine Oxidoreductase Enhances the Potential of Tyrosine Kinase Inhibitors against Chronic Myeloid Leukemia
by: Marta Romo-González, et al.
Published: (2020-01-01)

Genotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment
by: Monika Jaruskova, et al.
Published: (2017-04-01)

Synergistic lethality in chronic myeloid leukemia – targeting oxidative phosphorylation and unfolded protein response effectively complements tyrosine kinase inhibitor treatment
by: Lukas Häselbarth, et al.
Published: (2023-11-01)

Chronic Myeloid Leukemia Preceded by Tuberculosis
by: Bara M. Al-Qudah, et al.
Published: (2020-06-01)

Modelling of immune response in chronic myeloid leukemia patients suggests potential for treatment reduction prior to cessation
by: Elena Karg, et al.
Published: (2022-12-01)

Impact of BCR-ABL1 Transcript Type on Outcome in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors: A Pairwise and Bayesian Network Meta-Analysis
by: Kangkang Chen, et al.
Published: (2022-02-01)